Lupin Limited (NSE:LUPIN)
India · Delayed Price · Currency is INR | Market Cap | 1.04T +14.6% |
| Revenue (ttm) | 279.58B +23.1% |
| Net Income | 53.33B +62.5% |
| EPS | 116.44 +62.4% |
| Shares Out | n/a |
| PE Ratio | 19.49 |
| Forward PE | 22.60 |
| Dividend | 12.00 (0.53%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 39,467 |
| Open | 2,284.40 |
| Previous Close | 2,273.10 |
| Day's Range | 2,265.20 - 2,286.70 |
| 52-Week Range | 1,836.80 - 2,494.00 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 2,466.51 (+8.55%) |
| Earnings Date | Aug 4, 2026 |
About Lupin
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, ... [Read more]
Financial Performance
In fiscal year 2026, Lupin's revenue was 279.58 billion, an increase of 23.12% compared to the previous year's 227.08 billion. Earnings were 53.33 billion, an increase of 62.51%.
Financial StatementsAnalyst Summary
According to 37 analysts, the average rating for LUPIN stock is "Buy." The 12-month stock price target is ₹2,467, which is an increase of 8.55% from the latest price.
News
Lupin collaboraters with Spain’s ERN to launch Luforbec for Asthma and COPD treatment
Pharmaceutical major Lupin Limited has announced a strategic collaboration with LABORATORIOS ERN S.A. for the launch of Luforbec® (beclometasone/formoterol) 100/6 in Spain. The product is a fixed-dose...
Lupin Wins FDA Approval For Ranluspec Biosimilar To Lucentis
(RTTNews) - Lupin Ltd., (NSE: LUPIN) announced that the U.S. FDA has approved Ranluspec (ranibizumab-hkdz), its interchangeable biosimilar to Lucentis (Genentech). The approval covers both vial and pr...
Lupin And Natco Receive FDA Approval For Eribulin Mesylate Injection
(RTTNews) - Lupin Limited (LUPIN) and its alliance partner Natco Pharma Limited announced that the U.S FDA has approved Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection,...
Natco Pharma and Lupin secure U.S. FDA approval for Eribulin Mesylate Injection
Natco Pharma Limited and its alliance partner Lupin Limited have received approval from the United States Food and Drug Administration (U.S. FDA) for Natco’s Abbreviated New Drug Application (ANDA) fo...
Lupin Receives U.S. FDA Approval For Generic Sutab Tablets
(RTTNews) - Lupin Limited announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Sodium Sulfate, Magnesium Sulf...
Lupin Secures China Approval For Oseltamivir Oral Suspension, Marking Its Market Debut
(RTTNews) - Lupin Limited (LUPIN) has received regulatory approval in China for its Oseltamivir Phosphate Oral Suspension, marking the company's first-ever product entry into the Chinese pharmaceutica...
Lupin Transcript: Q4 25/26
Record FY 2026 results with 23% revenue and 55% EBITDA growth, driven by strong U.S., India, and emerging market performance. FY 2027 guidance targets high single-digit revenue growth and 25% EBITDA margin, factoring in increased competition and new product launches.
Lupin Quarterly report: Q4 2026
Lupin has published its Q4 2026 quarterly earnings report on May 8, 2026.
Lupin Slides: Q4 2026
Lupin has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 8, 2026.
Lupin secures USFDA approval for rare disease drug with $337 million opportunity
Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Glycerol Phenylbutyrate Oral L...
Lupin launches Dapagliflozin and Metformin Extended-Release Tablets in the U.S. after FDA approval
Indian pharma major Lupin Limited has announced the launch of its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States, marking another significant step in its expan...
Lupin Receives Tentative U.S. FDA Approval For Sugammadex Injection
(RTTNews) - Lupin Limited (Lupin) has received tentative approval from the U.S. FDA for its generic Sugammadex Injection, available in 200 mg/2 mL and 500 mg/5 mL single-dose vials. The product is a g...
Lupin receives tentative approval from U.S. FDA for Sugammadex Injection
Lupin Limited has announced a significant milestone with the receipt of tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Sugammadex Injection. This approval pe...
Lupin subsidiary Nanomi increases stake in Multicare Pharmaceuticals Philippines to 56.28%
Lupin Limited has announced that its subsidiary, Nanomi B.V., has increased its stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) from 51% to 56.28%. This development follows a buyback of 2,...
Lupin receives tentative U.S. FDA approval for Pitolisant Tablets
Lupin Limited, a global pharmaceutical leader, has announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Applica...
Lupin announces expansion of Dabhasa manufacturing facility
Lupin Manufacturing Solutions (LMS), a subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic expansion of its manufacturing facility in Dabhasa, India. This expansion...
Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025
MUMBAI, India, March 6, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced its recognition among the top 1...
Lupin Goa facility clears US FDA inspection with VAI classification
Lupin Limited (Lupin) has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA)...
Lupin receives USFDA approval for Brivaracetam Oral Solution, launches in US market
Lupin Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA)...
Lupin signs licensing and supply agreement with Spektus Pharma to commercialise DeslaFlex in Canada
Lupin Limited has signed a licence and supply agreement with Spektus Pharma to commercialise DeslaFlex™ in Canada, strengthening its central...
Lupin Transcript: Q3 25/26
Q3 FY26 saw record revenue and EBITDA, with broad-based growth across all regions and strong U.S. performance. Key launches, biosimilar approvals, and strategic acquisitions support a positive outlook, with EBITDA margin guidance raised and robust R&D investment continuing.
Lupin Quarterly report: Q3 2026
Lupin has published its Q3 2026 quarterly earnings report on February 13, 2026.
Lupin Slides: Q3 2026
Lupin has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Lupin launches Topiramate Extended-Release Capsules in the US after FDA approval
Lupin Limited has announced the launch of Topiramate Extended-Release Capsules in the United States, marking another key addition to its...
Lupin collaborates with TB Alliance to advance new treatment for Tuberculosis and other mycobacterial diseases
Lupin Limited has announced a strategic collaboration with TB Alliance to support the clinical development and future commercialization of the...